Abstract: Disclosed is an application of methioninase gene therapy in the treatment of a malignant tumor. In the gene therapy, a virus is used as a vector to insert an exogenous methioninase gene to constitute a methioninase expression system inside a tumor, thus providing an endogenous mechanism for further consumption of methionine. In vitro cytology experiments indicate that the methioninase gene therapy significantly reduces the level of intracellular methionine, effectively inhibits the proliferation of tumor cells, and can be used in an application in preparing a drug for the targeted treatment of a malignant tumor.

Abstract: A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases.

Abstract: Disclosed in the present disclosure are a potassium salt crystal form B of a phosphodiesterase type 5 inhibitor, and a preparation method and a use therefor. The structural formula of the phosphodiesterase type 5 inhibitor is as shown in a formula (I), and the X-ray powder diffraction (XRPD) pattern of the potassium salt crystal form B has characteristic peaks at the following 2? angles: 5.71°±0.2°, 8.23°±0.2°, 11.37°±0.2°, 13.22°±0.2°, 17.09°±0.2°, 21.56°±0.2°, 23.99°±0.2°, and 25.85°±0.2°. Further disclosed in the present disclosure is a use for the present crystal form potassium salt in preparing drugs for treating pulmonary hypertension, idiopathic pulmonary fibrosis, renal fibrosis, myocardial hypertrophy, or erectile dysfunction.

Abstract: Provided is use of a genetically engineered bacterium of attenuated Salmonella typhimurium for treating liver cancer. The bacterium is attenuated Salmonella typhimurium VNP20009 carrying a plasmid cloned with a methioninase gene. Also provided is a construction method of the bacterium.

Abstract: Provided is use of a genetically engineered bacterium of attenuated Salmonella typhimurium for treating liver cancer. The bacterium is attenuated Salmonella typhimurium VNP20009 carrying a plasmid cloned with a methioninase gene. Also provided is a construction method of the bacterium.

Abstract: Provided is an application of a genetically engineered bacterium of attenuated Salmonella typhimurium in preparation of medicines for treating liver cancer. The bacterium is attenuated Salmonella typhimurium VNP20009 carrying a plasmid cloned with a methioninase gene. Also provided is a construction method of the bacterium.

Abstract: The present disclosure provides uses of genetically engineered attenuated Salmonella typhimurium strain VNP20009-M in preventing and treating cancer metastasis. The genetically engineered strain VNP20009-M is targeted to cancer cells and has a significant effect of inhibiting metastasis and growth. VNP20009-M can be used to prepare medicaments for the prevention and treatment of tumor metastasis.

Abstract: The current invention discloses an attenuated Salmonella typhimurium, a genetically engineered bacterium and applications thereof in preparing drugs for the treatment of prostate cancer. The attenuated Salmonella typhimurium has tumor targeting and significant inhibitory effects on prostate cancer cells. A genetically engineered bacterium bearing a L-methioninase gene plasmid also has tumor targeting ability. The attenuated Salmonella typhimurium with the plasmid can constitutively express L-methioninase in the tumor tissues, consume a significant amount of methionine and other nutrients, which in turn causes lack of nutrition and slow growth of tumor cells. Therefore, it can be used as drugs for treating prostate cancer.